Profile picture
, 4 tweets, 4 min read
My Authors
Read all threads
This simple #SARSCoV2 saliva test costs $1, gets results in <1 hour, and can be performed anywhere without electricity
medrxiv.org/content/10.110… by @PrakashLab
Why isn't there US support to get rapid validation of such tests and provided to every household?
For a very good review of all the better types of tests in the hopper
cell.com/matter/pdf/S25…
Here's another excellent view of the landscape of the rapid tests
nature.com/articles/d4158…
Yup, that's the multibillion $ question
usatoday.com/story/news/hea…
by @kweintraub @USATODAYhealth w/ @michaelmina_lab
via @dho
✓ @UWMadison data
Missing some Tweet in this thread? You can try to force a refresh.

Keep Current with Eric Topol

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Related hashtags

#SARSCoV2

More from @EricTopol see all

Profile picture
Eric Topol
@EricTopol
1. The early use of inhaled interferons is emerging as a promising strategy to prevent severe #COVID19: lines of support include mechanism, rare genomic variants, a multicenter retrospective report, and a small randomized trial
2. On mechanism, our innate immune response, first line of defense relies, at least in part, on the interferon response.
2 figures from @VirusesImmunity's terrific thread, and the link to it
3. Yesterday's @JAMA_Current report of loss-of-function TRL7 rare variants in 4 young men from 2 independent families w/ severe #COVID19 connects with their impaired interferon response
Editorial @rplenge jamanetwork.com/journals/jama/…
Paper by @ahoischen et al jamanetwork.com/journals/jama/…
Read 8 tweets
Profile picture
Eric Topol
@EricTopol
Very sad to note that today is the first day since May 29th (>6 weeks ago) there were more than 1,000 American #COVID19 deaths
@COVID19Tracking
> 8 weeks (not 6, my mistake)
We haven't seen this level of US #COVID19 hospitalizations since the April 15th peak
While attention has focused on Texas, Arizona, and Florida, many news states have hit new hospitalization and death numbers recently or today. Including South Carolina, Mississippi, Georgia, Tennessee and Idaho
Read 4 tweets
Profile picture
Eric Topol
@EricTopol
On the 4 published Phase 1/2 #SARSCoV2 vaccine programs
(@moderna_tx @UniofOxford @Pfizer CanSino)
1. None have shown prevention of infections or disease; they show an antibody response, some T cell response, and preliminary safety. Can't be emphasized enough.
2. We have no idea about durability. The virus is only ~8 months old!
3. Only 2 of these programs presented specific T-cell response data (perhaps a proxy for longer-lasting protection):
Pfizer/BioNTech program CD4+ in 34/36 patients, CD8+ 29/36 patients
Moderna mostly only CD4+
References for T cell data
Pfizer/BioNTech
medrxiv.org/content/10.110…
Moderna nejm.org/doi/suppl/10.1…
Read 4 tweets

Embed code for your website

×
Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!